Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes

Molecular Therapy

Volumn 21, Issue 4, 2013, Pages 816-824

  Shim, Gayong ^a   Choi, Hyun Woo ^a   Lee, Sangbin ^b   Choi, Junhyeok ^a   Yu, Yong Hee ^a   Park, Da Eui ^a   Choi, Yongseok ^b   Kim, Chan Wha ^a   Oh, Yu Kyoung ^a  

^a Seoul National University   (South Korea)

^b Korea University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DI O OCTADECENYL 3 TRIMETHYLAMMONIUM PROPANE; 1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 1,2 DIOLEOYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; 3 BETA [N (N',N' DIMETHYLAMINO ETHANE)CARBAMOYL]CHOLESTEROL; CHOLESTEROL; DIOLEOYL SN GLYCERO 3 ETHYLPHOSPHOCHOLINE; LIPOSOME; MESSENGER RNA; PROTEIN MCL 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CELL FUNCTION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; LUNG NODULE; MOUSE; NONHUMAN; TISSUE LEVEL;

EID: 84878559366     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.10     Document Type: Article

References (45)

1. Chen, SH and Zhaori, G (2011). Potential clinical applications of siRNA technique: benefts and limitations. Eur J Clin Invest 41: 221-232.
2. Burnett, JC, Rossi, JJ and Tiemann, K (2011). Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 6: 1130-1146.
3. Oh, YK and Park, TG (2009). siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 61: 850-862.
4. Wang, J, Lu, Z, Wientjes, MG and Au, JL (2010). Delivery of siRNA therapeutics: barriers and carriers. AAPS J 12: 492-503.
5. Shim, MS and Kwon, YJ (2010). Effcient and targeted delivery of siRNA in vivo. FEBS J 277: 4814-4827.
6. Durcan, N, Murphy, C and Cryan, SA (2008). Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol Pharm 5: 559-566.
7. Polach, KJ, Matar, M, Rice, J, Slobodkin, G, Sparks, J, Congo, R et al. (2012). Delivery of siRNA to the mouse lung via a functionalized lipopolyamine. Mol Ther 20: 91-100.
8. Merkel, OM and Kissel, T (2012). Nonviral pulmonary delivery of siRNA. Acc Chem Res 45: 961-970.
9. Lam, JK, Liang, W and Chan, HK (2012). Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev 64: 1-15.
10. Moschos, SA, Frick, M, Taylor, B, Turnpenny, P, Graves, H, Spink, KG et al. (2011). Uptake, effcacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense. Mol Ther 19: 2163-2168.
11. Xu, CX, Jere, D, Jin, H, Chang, SH, Chung, YS, Shin, JY et al. (2008). Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis. Am J Respir Crit Care Med 178: 60-73.
12. Beyerle, A, Braun, A, Merkel, O, Koch, F, Kissel, T and Stoeger, T (2011). Comparative in vivo study of poly(ethylene imine)/siRNA complexes for pulmonary delivery in mice. J Control Release 151: 51-56.
13. Jensen, DK, Jensen, LB, Koocheki, S, Bengtson, L, Cun, D, Nielsen, HM et al. (2012). Design of an inhalable dry powder formulation of DOTAP-modifed PLGA nanoparticles loaded with siRNA. J Control Release 157: 141-148.
14. Taetz, S, Bochot, A, Surace, C, Arpicco, S, Renoir, JM, Schaefer, UF et al. (2009). Hyaluronic acid-modifed DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells. Oligonucleotides 19: 103-116.
15. Tagalakis, AD, He, L, Saraiva, L, Gustafsson, KT and Hart, SL (2011). Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery. Biomaterials 32: 6302-6315.
16. Matsumura, JS, Kim, R, Shively, VP, MacDonald, RC and Pearce, WH (1999). Characterization of vascular gene transfer using a novel cationic lipid. J Surg Res 85: 339-345.
17. Mahato, RI, Anwer, K, Tagliaferri, F, Meaney, C, Leonard, P, Wadhwa, MS et al. (1998). Biodistribution and gene expression of lipid/plasmid complexes after systemic administration. Hum Gene Ther 9: 2083-2099.
18. Mok, TS (2011). Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol 8: 661-668.
19. Writer, M, Hurley, CA, Sarkar, S, Copeman, DM, Wong, JB, Odlyha, M et al. (2006). Analysis and optimization of the cationic lipid component of a lipid/peptide vector formulation for enhanced transfection in vitro and in vivo. J Liposome Res 16: 373-389.
20. Zhang, Y, Li, H, Sun, J, Gao, J, Liu, W, Li, B et al. (2010). DC-Chol/DOPE cationic liposomes: a comparative study of the infuence factors on plasmid pDNA and siRNA gene delivery. Int J Pharm 390: 198-207.
21. MacDonald, RC, Rakhmanova, VA, Choi, KL, Rosenzweig, HS and Lahiri, MK (1999). O-ethylphosphatidylcholine: A metabolizable cationic phospholipid which is a serum-compatible DNA transfection agent. J Pharm Sci 88: 896-904.
22. Wang, L and MacDonald, RC (2007). Synergistic effect between components of mixtures of cationic amphipaths in transfection of primary endothelial cells. Mol Pharm 4: 615-623.
23. Noh, SM, Han, SE, Shim, G, Lee, KE, Kim, CW, Han, SS et al. (2011). Tocopheryl oligochitosan-based self assembling oligomersomes for siRNA delivery. Biomaterials 32: 849-857.
24. Bae, Y, Nishiyama, N and Kataoka, K (2007). In vivo antitumor activity of the folate-conjugated pH-sensitive polymeric micelle selectively releasing adriamycin in the intracellular acidic compartments. Bioconjug Chem 18: 1131-1139.
25. Moghimi, SM, Symonds, P, Murray, JC, Hunter, AC, Debska, G and Szewczyk, A (2005). A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther 11: 990-995.
26. Hunter, AC and Moghimi, SM (2010). Cationic carriers of genetic material and cell death: a mitochondrial tale. Biochim Biophys Acta 1797: 1203-1209.
27. Wang, L and MacDonald, RC (2011). Cationic phospholiposomes: effcient delivery vehicles of anticancer derivatives of ATP to multiple myeloma cells. J Liposome Res 21: 306-314.
28. Song, L, Coppola, D, Livingston, S, Cress, D and Haura, EB (2005). Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther 4: 267-276.
29. Simonin, K, Brotin, E, Dufort, S, Dutoit, S, Goux, D, N'diaye, M et al. (2009). Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells. Mol Cancer Ther 8: 3162-3170.
30. Luo, L, Zhang, T, Liu, H, Lv, T, Yuan, D, Yao, Y et al. (2012). MiR-101 and Mcl-1 in non-small-cell lung cancer: expression profle and clinical signifcance. Med Oncol 29: 1681-1686.
31. Zhou, W, Hu, J, Tang, H, Wang, D, Huang, X, He, C et al. (2011). Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors. BMC Cancer 11: 485.
32. Shim, G, Han, SE, Yu, YH, Lee, S, Lee, HY, Kim, K et al. (2011). Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. J Control Release 155: 60-66.
33. Yonenaga, N, Kenjo, E, Asai, T, Tsuruta, A, Shimizu, K, Dewa, T et al. (2012). RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment. J Control Release 160: 177-181.
34. Zhou, H, Roy, S, Cochran, E, Zouaoui, R, Chu, CL, Duffner, J et al. (2011). M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS ONE 6: e21106.
35. Chandenier, J, Bernard, S, Montharu, J, Bailly, E, Fetissof, F, de Monte, M et al. (2009). The utility of a nebulised intra-tracheal rat model of invasive pulmonary aspergillosis. Mycoses 52: 239-245.
36. Li, BJ, Tang, Q, Cheng, D, Qin, C, Xie, FY, Wei, Q et al. (2005). Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 11: 944-951.
37. MacDonald, RC, Ashley, GW, Shida, MM, Rakhmanova, VA, Tarahovsky, YS, Pantazatos, DP et al. (1999). Physical and biological properties of cationic triesters of phosphatidylcholine. Biophys J 77: 2612-2629.
38. Semple, SC, Akinc, A, Chen, J, Sandhu, AP, Mui, BL, Cho, CK et al. (2010). Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28: 172-176.
39. Akinc, A, Zumbuehl, A, Goldberg, M, Leshchiner, ES, Busini, V, Hossain, N et al. (2008). A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26: 561-569.
40. Heyes, J, Palmer, L, Bremner, K and MacLachlan, I (2005). Cationic lipid saturation infuences intracellular delivery of encapsulated nucleic acids. J Control Release 107: 276-287.
41. Aissaoui, A, Chami, M, Hussein, M and Miller, AD (2011). Effcient topical delivery of plasmid DNA to lung in vivo mediated by putative triggered, PEGylated pDNA nanoparticles. J Control Release 154: 275-284.
42. Mochizuki, S, Kanegae, N, Nishina, K, Kamikawa, Y, Koiwai, K, Masunaga, H et al. (2013). The role of the helper lipid dioleoylphosphatidylethanolamine (DOPE) for DNA transfection cooperating with a cationic lipid bearing ethylenediamine. Biochim Biophys Acta 1828: 412-418.
43. Zuhorn, IS, Bakowsky, U, Polushkin, E, Visser, WH, Stuart, MC, Engberts, JB et al. (2005). Nonbilayer phase of lipoplex-membrane mixture determines endosomal escape of genetic cargo and transfection effciency. Mol Ther 11: 801-810.
44. Yu, B, Hsu, SH, Zhou, C, Wang, X, Terp, MC, Wu, Y et al. (2012). Lipid nanoparticles for hepatic delivery of small interfering RNA. Biomaterials 33: 5924-5934.
45. Chang, RS, Suh, MS, Kim, S, Shim, G, Lee, S, Han, SS et al. (2011). Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA. Biomaterials 32: 9785-9795.